首页> 外文期刊>Hepato-gastroenterology. >Expression Status of Fatty Acid Synthase (FAS) but not HER2 is Correlated with the Differentiation Grade and Prognosis of Esophageal Carcinoma
【24h】

Expression Status of Fatty Acid Synthase (FAS) but not HER2 is Correlated with the Differentiation Grade and Prognosis of Esophageal Carcinoma

机译:脂肪酸合成酶(FAS)而不是HER2的表达状态与食管癌的分化程度和预后相关

获取原文
获取原文并翻译 | 示例
       

摘要

Background/Aims: Fatty acid synthase (FAS) and human epidermal growth factor receptor 2 (HER2) are overexpressed in a series of cancers. However, few studies have investigated the potential role of FAS and HER2 in esophageal carcinoma. The aim of this study was to evaluate the expression of FAS and HER2 and the possible link between FAS/HER2 expression and the pathological prognostic varibles. Methodology: The frequency of FAS and HER2 expression was determined immunohistochemically. The overall survival rate was analysed by the Kaplan-Meier method and the log-rank test using SPSS 17.0 software. Results: The majority of the cases were esophageal squamous cell carcinomas (n=142). FAS and HER2 overexpression in the studied cases are 73.2% and 14.1%, respectively. There was a significant difference in FAS expression regarding tumor differentiation and FAS overexpression showed its prognostic value for patients with different tumor differentiation. Meanwhile, HER2 overexpression did not significantly relate to the clinicopathological characteristics of the tumors, with the only exception of the surgical margins. Conclusions: FAS and HER2 overexpression are common in esophageal carcinomas. FAS overexpression showed its prognostic value for esophageal carcinoma patients with different tumor differentiation, which lead us to consider FAS-inhibitors as potential candidates for target-based adjuvant therapies.
机译:背景/目的:脂肪酸合酶(FAS)和人表皮生长因子受体2(HER2)在一系列癌症中过表达。但是,很少有研究调查FAS和HER​​2在食管癌中的潜在作用。这项研究的目的是评估FAS和HER​​2的表达以及FAS / HER2表达与病理预后变量之间的可能联系。方法:免疫组化测定FAS和HER​​2表达的频率。通过Kaplan-Meier方法和使用SPSS 17.0软件的对数秩检验分析了总生存率。结果:大多数病例为食管鳞状细胞癌(n = 142)。在研究案例中,FAS和HER​​2的过表达分别为73.2%和14.1%。在肿瘤分化方面,FAS表达存在显着差异,FAS过表达显示出其对不同肿瘤分化患者的预后价值。同时,除手术切缘外,HER2的过表达与肿瘤的临床病理特征没有显着关系。结论:FAS和HER​​2过表达在食管癌中很常见。 FAS的过表达对具有不同肿瘤分化的食道癌患者具有预后价值,这使我们考虑将FAS抑制剂视为基于靶标的辅助疗法的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号